Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 10 (2010), Pages 1107-1120
http://dx.doi.org/10.1100/tsw.2010.103
Review Article

Therapeutic Antibodies for the Treatment of Pancreatic Cancer

INSERM U624, GDR2352, Marseille Cedex, France

Received 16 March 2010; Revised 4 May 2010; Accepted 7 May 2010

Academic Editors: Juan Iovanna and Jose Neira

Copyright © 2010 Patrick Chames et al.

Citations to this Article [10 citations]

The following is the list of published articles that have cited the current article.

  • Juan Iovanna, and Jose Luis Neira, “Pancreatic Cancer: Molecular, Biochemical, Chemopreventive, and Therapeutic Aspects,” Thescientificworldjournal, vol. 10, pp. 1967–1970, 2010. View at Publisher · View at Google Scholar
  • Birgit Hotz, Hubert G. Hotz, and Heinz-Johannes Buhr, “Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?,” Anti-Cancer Agents In Medicinal Chemistry, vol. 11, no. 5, pp. 448–454, 2011. View at Publisher · View at Google Scholar
  • Xu Liu, Xiao-Zhong Guo, Wei-Wei Zhang, Zhuo-Zhuang Lu, Qun-Wei Zhang, Hai-Feng Duan, and Li-Sheng Wang, “KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity,” Hepatobiliary & Pancreatic Diseases International, vol. 10, no. 2, pp. 201–208, 2011. View at Publisher · View at Google Scholar
  • Yun-Hee Kim, Ho Jin Sung, Sukyoung Kim, Eun-Ok Kim, Ji Won Lee, Ju Young Moon, Kyungho Choi, Ji-Eun Jung, Yangsoon Lee, Sang Seok Koh, Sue Goo Rhee, Kyun Heo, and In-Hoo Kim, “An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells,” Cancer Letters, vol. 313, no. 1, pp. 76–83, 2011. View at Publisher · View at Google Scholar
  • Su Jin Kim, Suhwan Chang, Yangsoon Lee, Na Young Kim, Yeonsil Hwang, Hye Jin Min, Kyung-Sook Yoo, Eun Hye Park, Seokho Kim, Young-Hwa Chung, Young Woo Park, and Sang Seok Koh, “A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis,” Biochemical and Biophysical Research Communications, 2014. View at Publisher · View at Google Scholar
  • Aoife S Crawley, and Richard J O’Kennedy, “The need for effective pancreatic cancer detection and management: a biomarker-based strategy,” Expert Review of Molecular Diagnostics, vol. 15, no. 10, pp. 1339–1353, 2015. View at Publisher · View at Google Scholar
  • Feng Jiao, Hai Hu, Ting Han, Meng Zhuo, Lei Wang, Liwei Wang, Cuncun Yuan, and Haiyan Yang, “Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer,” Oncotarget, vol. 7, no. 13, pp. 16505–16516, 2016. View at Publisher · View at Google Scholar
  • Shailendra K. Gautam, Sushil Kumar, Andrew Cannon, Bradley Hall, Rakesh Bhatia, Mohd Wasim Nasser, Sidharth Mahapatra, Surinder K. Batra, and Maneesh Jain, “MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma,” Expert Opinion on Therapeutic Targets, pp. 1–13, 2017. View at Publisher · View at Google Scholar
  • Jieying Li, Qin Jin, Fang Huang, Zhiyuan Tang, and Jianfei Huang, “Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells,” Pancreas, vol. 46, no. 9, pp. 1173–1179, 2017. View at Publisher · View at Google Scholar
  • Simranjeet Singh Sekhon, Hyun-Ju Um, Woo-Ri Shin, Sang-Hee Lee, Jiho Min, Ji-Young Ahn, and Yang-Hoon Kim, “Aptabody–aptatope interactions in aptablotting assays,” Nanoscale, 2017. View at Publisher · View at Google Scholar